Clinical trial · no report yet · Phase 2/Phase 3

IZABRIGHT-Lung01

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080 ↗
Recruiting
Bristol-Myers Squibb
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	8

The trial

ClinicalTrials.gov

Official title: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
Phase: Phase 2/Phase 3
Status: Recruiting
Conditions: Non-Small Cell Lung Cancer
Interventions: Iza-bren; Carboplatin; Cisplatin; Pemetrexed
Arms: Arm A · Experimental
Arm B · Experimental
Arm C · Active comparator
Arm D · Experimental
Arm E · Active comparator
Enrollment: 500 (estimated)
Primary outcomes: Recommended Phase 3 Dose (RP3D) of BMS-986507
Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)
Sponsor: Bristol-Myers Squibb
Start: Nov 5, 2025
Primary completion: Dec 15, 2028 (estimated)
Results posted: No
Registry record: NCT07100080 · updated Oct 9, 2026